Benzinga · Mar 4, 2026
KL
NASDAQ · KLTOW
Klotho Neurosciences, Inc.
Healthcare · Biotechnology
$0.09
Down-$0.01 (-9.28%)
Updated Sep 12, 2026, 8:18 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.28M
- P/E ratio
- -2.25
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.95
- Volume
- 18.67K
- Avg. volume
- 119.09K
Price performance
KLTOW price history
1M range · 0 trading sessions · Daily adjusted prices
KLTOW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest KLTOW news
The latest Smart Investors Daily articles mentioning KLTOW.
Stock researchCompany · Overview
KLTOW research
Overview
Company profile and research snapshot.
Company profile
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
